Literature DB >> 18245550

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.

Alissa Huston1, Xavier Leleu, Xiaoying Jia, Anne-Sophie Moreau, Hai T Ngo, Judith Runnels, Judy Anderson, Yazan Alsayed, Aldo Roccaro, Sonia Vallet, Evdoxia Hatjiharissi, Yu-Tsu Tai, Peter Sportelli, Nikhil Munshi, Paul Richardson, Teru Hideshima, David G Roodman, Kenneth C Anderson, Irene M Ghobrial.   

Abstract

PURPOSE: We hypothesized that targeting both Akt and heat shock protein (HSP) 90 would induce cytotoxic activity against multiple myeloma (MM) cells and target the bone marrow (BM) microenvironment to inhibit angiogenesis, osteoclast formation, as well as migration and adhesion of MM cells. EXPERIMENTAL
DESIGN: MM cell lines were incubated with perifosine (5 and 10 micromol/L) and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG; 50 and 100 nmol/L) alone and in combination.
RESULTS: The combination of Akt inhibitor perifosine and HSP90 inhibitor 17-DMAG was synergistic in inducing MM cell cytotoxicity, evidenced by inhibition of DNA synthesis and induction of apoptosis. In addition, perifosine and 17-DMAG almost completely inhibited osteoclast formation: perifosine interfered with both early and late stages of osteoclast progenitor development, whereas 17-DMAG targeted only early stages. We next showed that combined therapy overcomes tumor growth and resistance induced by BM stromal cells and endothelial cells as well as the proliferative effect of exogenous interleukin-6, insulin-like growth factor-I, and vascular endothelial growth factor. Moreover, the combination also induced apoptosis and growth inhibition in endothelial cells and inhibited angiogenesis. Finally, we showed that the two agents prevented migration of MM cells toward stromal-derived factor-1 and vascular endothelial growth factor, which are present in the BM milieu, and also prevented adhesion of MM cells to fibronectin.
CONCLUSIONS: This study provides the preclinical framework for treatment protocols targeting both the Akt and HSP pathways in MM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245550     DOI: 10.1158/1078-0432.CCR-07-1299

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Perifosine: update on a novel Akt inhibitor.

Authors:  Joell J Gills; Phillip A Dennis
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

2.  A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer.

Authors:  Elizabeth R Remily-Wood; Richard Z Liu; Yun Xiang; Yi Chen; C Eric Thomas; Neal Rajyaguru; Laura M Kaufman; Joana E Ochoa; Lori Hazlehurst; Javier Pinilla-Ibarz; Jeffrey Lancet; Guolin Zhang; Eric Haura; David Shibata; Timothy Yeatman; Keiran S M Smalley; William S Dalton; Emina Huang; Ed Scott; Gregory C Bloom; Steven A Eschrich; John M Koomen
Journal:  Proteomics Clin Appl       Date:  2011-06-08       Impact factor: 3.494

3.  Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.

Authors:  Siqing Fu; Bryan T Hennessy; Chaan S Ng; Zhenlin Ju; Kevin R Coombes; Judith K Wolf; Anil K Sood; Charles F Levenback; Robert L Coleman; John J Kavanagh; David M Gershenson; Maurie Markman; Kristine Dice; Adrienne Howard; Jane Li; Yang Li; Katherine Stemke-Hale; Mary Dyer; Edward Atkinson; Ed Jackson; Vikas Kundra; Razelle Kurzrock; Robert C Bast; Gordon B Mills
Journal:  Gynecol Oncol       Date:  2012-04-06       Impact factor: 5.482

4.  The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.

Authors:  Manik Chatterjee; Mindaugas Andrulis; Thorsten Stühmer; Elisabeth Müller; Claudia Hofmann; Torsten Steinbrunn; Tanja Heimberger; Heike Schraud; Stefanie Kressmann; Hermann Einsele; Ralf C Bargou
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 5.  Targeted therapies in multiple myeloma.

Authors:  Efstathios Kastritis; Andreas Charidimou; Andreas Varkaris; Meletios A Dimopoulos
Journal:  Target Oncol       Date:  2009-01-17       Impact factor: 4.493

Review 6.  Emerging therapies for multiple myeloma.

Authors:  Klaus Podar; Yu-Tzu Tai; Teru Hideshima; Sonia Vallet; Paul G Richardson; Kenneth C Anderson
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

7.  Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.

Authors:  Jordi Codony-Servat; Santiago Viteri; Carles Codony-Servat; Masaoki Ito; Jillian Willhelmina Paulina Bracht; Jordi Berenguer; Imane Chaib; Miguel Angel Molina-Vila; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2019-08

Review 8.  Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.

Authors:  Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Journal:  Drug Resist Updat       Date:  2009-04-22       Impact factor: 18.500

9.  Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.

Authors:  Weili Sun; Shakeel Modak
Journal:  Onco Targets Ther       Date:  2012-03-02       Impact factor: 4.147

Review 10.  DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Authors:  Lauren I Aronson; Faith E Davies
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.